Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

38 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
The efficacy and safety of pertuzumab plus trastuzumab and docetaxel as a first-line therapy in Japanese patients with inoperable or recurrent HER2-positive breast cancer: the COMACHI study.
Takahashi M, Ohtani S, Nagai SE, Takashima S, Yamaguchi M, Tsuneizumi M, Komoike Y, Osako T, Ito Y, Ikeda M, Ishida K, Nakayama T, Takashima T, Asakawa T, Matsumoto S, Shimizu D, Masuda N. Takahashi M, et al. Among authors: tsuneizumi m. Breast Cancer Res Treat. 2021 Jan;185(1):125-134. doi: 10.1007/s10549-020-05921-x. Epub 2020 Sep 13. Breast Cancer Res Treat. 2021. PMID: 32920732 Free PMC article. Clinical Trial.
Treatment outcomes and prognostic factors for patients with brain metastases from breast cancer of each subtype: a multicenter retrospective analysis.
Niikura N, Hayashi N, Masuda N, Takashima S, Nakamura R, Watanabe K, Kanbayashi C, Ishida M, Hozumi Y, Tsuneizumi M, Kondo N, Naito Y, Honda Y, Matsui A, Fujisawa T, Oshitanai R, Yasojima H, Tokuda Y, Saji S, Iwata H. Niikura N, et al. Among authors: tsuneizumi m. Breast Cancer Res Treat. 2014 Aug;147(1):103-12. doi: 10.1007/s10549-014-3090-8. Epub 2014 Aug 9. Breast Cancer Res Treat. 2014. PMID: 25106661
Prognostic factors of HER2-positive breast cancer patients who develop brain metastasis: a multicenter retrospective analysis.
Hayashi N, Niikura N, Masuda N, Takashima S, Nakamura R, Watanabe K, Kanbayashi C, Ishida M, Hozumi Y, Tsuneizumi M, Kondo N, Naito Y, Honda Y, Matsui A, Fujisawa T, Oshitanai R, Yasojima H, Yamauchi H, Saji S, Iwata H. Hayashi N, et al. Among authors: tsuneizumi m. Breast Cancer Res Treat. 2015 Jan;149(1):277-84. doi: 10.1007/s10549-014-3237-7. Epub 2014 Dec 21. Breast Cancer Res Treat. 2015. PMID: 25528021
Durable complete response in HER2-positive breast cancer: a multicenter retrospective analysis.
Niikura N, Shimomura A, Fukatsu Y, Sawaki M, Ogiya R, Yasojima H, Fujisawa T, Yamamoto M, Tsuneizumi M, Kitani A, Watanabe J, Matsui A, Takahashi Y, Takashima S, Shien T, Tamura K, Saji S, Masuda N, Tokuda Y, Iwata H. Niikura N, et al. Among authors: tsuneizumi m. Breast Cancer Res Treat. 2018 Jan;167(1):81-87. doi: 10.1007/s10549-017-4489-9. Epub 2017 Sep 11. Breast Cancer Res Treat. 2018. PMID: 28895005 Clinical Trial.
Comparison of immune microenvironments between primary tumors and brain metastases in patients with breast cancer.
Ogiya R, Niikura N, Kumaki N, Yasojima H, Iwasa T, Kanbayashi C, Oshitanai R, Tsuneizumi M, Watanabe KI, Matsui A, Fujisawa T, Saji S, Masuda N, Tokuda Y, Iwata H. Ogiya R, et al. Among authors: tsuneizumi m. Oncotarget. 2017 Oct 27;8(61):103671-103681. doi: 10.18632/oncotarget.22110. eCollection 2017 Nov 28. Oncotarget. 2017. PMID: 29262592 Free PMC article.
A randomized phase II study evaluating pyridoxine for the prevention of hand-foot syndrome associated with capecitabine therapy for advanced or metastatic breast cancer.
Toyama T, Yoshimura A, Hayashi T, Kobayashi N, Saito K, Tsuneizumi M, Sawaki M, Hattori M, Nakada T, Yokota I, Iwata H. Toyama T, et al. Among authors: tsuneizumi m. Breast Cancer. 2018 Nov;25(6):729-735. doi: 10.1007/s12282-018-0879-z. Epub 2018 Jun 8. Breast Cancer. 2018. PMID: 29948956 Clinical Trial.
Randomized Controlled Trial of Trastuzumab With or Without Chemotherapy for HER2-Positive Early Breast Cancer in Older Patients.
Sawaki M, Taira N, Uemura Y, Saito T, Baba S, Kobayashi K, Kawashima H, Tsuneizumi M, Sagawa N, Bando H, Takahashi M, Yamaguchi M, Takashima T, Nakayama T, Kashiwaba M, Mizuno T, Yamamoto Y, Iwata H, Kawahara T, Ohashi Y, Mukai H; RESPECT study group. Sawaki M, et al. Among authors: tsuneizumi m. J Clin Oncol. 2020 Nov 10;38(32):3743-3752. doi: 10.1200/JCO.20.00184. Epub 2020 Sep 16. J Clin Oncol. 2020. PMID: 32936713 Clinical Trial.
Health-Related Quality of Life With Trastuzumab Monotherapy Versus Trastuzumab Plus Standard Chemotherapy as Adjuvant Therapy in Older Patients With HER2-Positive Breast Cancer.
Taira N, Sawaki M, Uemura Y, Saito T, Baba S, Kobayashi K, Kawashima H, Tsuneizumi M, Sagawa N, Bando H, Takahashi M, Yamaguchi M, Takashima T, Nakayama T, Kashiwaba M, Mizuno T, Yamamoto Y, Iwata H, Ohashi Y, Mukai H, Kawahara T; RESPECT Study Group. Taira N, et al. Among authors: tsuneizumi m. J Clin Oncol. 2021 Aug 1;39(22):2452-2462. doi: 10.1200/JCO.20.02751. Epub 2021 Apr 9. J Clin Oncol. 2021. PMID: 33835842
Adjuvant trastuzumab without chemotherapy for treating early HER2-positive breast cancer in older patients: A propensity score-adjusted analysis of a prospective cohort study.
Sawaki M, Taira N, Uemura Y, Saito T, Baba S, Kobayashi K, Kawashima H, Tsuneizumi M, Sagawa N, Bando H, Takahashi M, Yamaguchi M, Takashima T, Nakayama T, Kashiwaba M, Mizuno T, Yamamoto Y, Iwata H, Toyama T, Tsugawa K, Kawahara T, Mukai H; RESPECT study group. Sawaki M, et al. Among authors: tsuneizumi m. Breast. 2022 Dec;66:245-254. doi: 10.1016/j.breast.2022.10.017. Epub 2022 Nov 7. Breast. 2022. PMID: 36371994 Free PMC article. Clinical Trial.
38 results